MCID: LYM118
MIFTS: 71

Lymphoma

Categories: Neuronal diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoma

Summaries for Lymphoma

MedlinePlus : 40 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses substances that attack cancer cells without harming normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to lymphoma, hodgkin, classic and follicular lymphoma. An important gene associated with Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Endometrial cancer and PI3K-Akt signaling pathway. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 72 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1501)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 34.6 ALK BCL3 BCL6
2 follicular lymphoma 34.5 BCL10 BCL2 BCL6 CCND1 CXCR5 MYC
3 lymphoma, mucosa-associated lymphoid type 34.4 BCL10 BCL2 BCL6 CCND1 CXCR5 MALT1
4 follicular lymphoma 1 34.4 BCL10 BCL2 BCL6
5 peripheral t-cell lymphoma 34.4 ALK BCL6 TCL1A
6 primary effusion lymphoma 34.3 BCL6 MYC TCL1A
7 diffuse large b-cell lymphoma 34.3 ALK BCL10 BCL6 CCND1 MALT1 MYC
8 mantle cell lymphoma 34.3 ATM BCL2 BCL6 CCND1 MYC
9 gastric lymphoma 34.3 BAX BCL10 BCL2 BCL6
10 burkitt lymphoma 34.2 BAX BCL6 BCL7A BCL7B CXCR5 MYC
11 lymphoma, small cleaved-cell, diffuse 34.0 BCL2 CCND1
12 marginal zone b-cell lymphoma 34.0 BCL10 BCL2 BCL6 CCND1 MALT1
13 alk-negative anaplastic large cell lymphoma 33.9 ALK BAX BCL2
14 nodal marginal zone b-cell lymphoma 33.9 BCL2 BCL6 MALT1
15 primary cutaneous marginal zone b-cell lymphoma 33.9 BCL10 MALT1
16 b-cell lymphomas 33.8 BAX BCL10 BCL2 BCL3 BCL6 CCND1
17 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 33.8 BCL6 CXCR5
18 diffuse large b-cell lymphoma of the central nervous system 33.8 BCL2 MYC
19 breast lymphoma 33.7 ALK BCL6
20 nodular lymphocyte predominant hodgkin lymphoma 33.7 BCL6 CCND1
21 intravascular large b-cell lymphoma 33.7 BCL2 BCL6
22 lymphoma, non-hodgkin, familial 33.6 ALK ATM BAX BCL10 BCL2 BCL3
23 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 33.4 BCL2 BCL6 MYC
24 precursor t-cell acute lymphoblastic leukemia 32.7 BAX BCL10 MYC TCL1A
25 leukemia, chronic lymphocytic 32.1 ATM BAX BCL10 BCL2 BCL3 BCL6
26 prolymphocytic leukemia 30.5 ATM CCND1 MYC TCL1A
27 t-cell prolymphocytic leukemia 30.3 ATM MYC TCL1A
28 extramedullary plasmacytoma 29.9 BCL2 CCND1
29 nasopharyngeal carcinoma 29.9 BCL2 BCL3 CCND1 MYC
30 li-fraumeni syndrome 29.7 ATM BAX BCL2
31 suppressor of tumorigenicity 3 29.7 BAX BCL2 MYC
32 anaplastic large cell lymphoma 12.4
33 primary central nervous system lymphoma 12.4
34 plasmablastic lymphoma 12.3
35 gray zone lymphoma 12.3
36 cutaneous t cell lymphoma 12.3
37 lymphoblastic lymphoma 12.3
38 thyroid lymphoma 12.3
39 intraocular lymphoma 12.3
40 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 12.3
41 extranodal nasal nk/t cell lymphoma 12.3
42 splenic marginal zone lymphoma 12.2
43 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 12.2
44 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 12.2
45 primary cutaneous follicle center lymphoma 12.2
46 composite lymphoma 12.1
47 t-cell/histiocyte rich large b cell lymphoma 12.1
48 central nervous system lymphoma 12.1
49 bone lymphoma 12.1
50 lymphoma, large-cell, immunoblastic 12.1

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

GenomeRNAi Phenotypes related to Lymphoma according to GeneCards Suite gene sharing:

25 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.33 CTAGE1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.33 CTAGE1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.33 CTAGE1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.33 ATM
5 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.33 BCL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.33 ATM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.33 ATM
8 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.33 CTAGE1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.33 BCL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.33 BCL2 ATM
11 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.33 BCL7C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.33 CTAGE1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.33 BCL7C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.33 ATM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.33 ATM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.33 CTAGE1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.33 BCL2 ATM BCL7C CTAGE1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.33 ATM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.33 CTAGE1 BCL2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.33 CTAGE1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.33 BCL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.33 BCL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.33 BCL7C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.33 BCL2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.33 ATM CTAGE1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.33 ATM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.33 BCL7C
28 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.33 CTAGE1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.33 BCL2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.33 CTAGE1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.33 ATM
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.33 CTAGE1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.33 BCL7C
34 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.33 BCL2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.33 CTAGE1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.33 ATM
37 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.33 ATM
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.33 ATM BCL2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.33 BCL2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.33 BCL2
41 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 MALT1 ATM BAX BCL10 BCL2
42 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 MALT1 MYC ATM CCND1 BAX BCL10

MGI Mouse Phenotypes related to Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 MYC TIAM1 CXCR5 BCL11B BCL2 ATM
2 hematopoietic system MP:0005397 10.03 MYC BCL11B MALT1 BCL2 ATM BCL3
3 endocrine/exocrine gland MP:0005379 10.02 MYC BCL11B ALK BCL2 ATM BAX
4 immune system MP:0005387 9.93 MYC MALT1 BCL11B BCL2 ATM BCL3
5 mortality/aging MP:0010768 9.77 MYC MALT1 BCL11B ALK BCL2 ATM
6 neoplasm MP:0002006 9.23 TIAM1 MYC ALK BCL2 ATM BAX

Drugs & Therapeutics for Lymphoma

FDA approved drugs:

(show all 27)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 45 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 17 45 NELARABINE GlaxoSmithKline October 2005
3
Arzerra 17 45 OFATUMUMAB GlaxoSmithKline October 2009
4
Beleodaq 17 45 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Bexxar 17 45 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
6
Busulfex 17 45 BUSULFAN Orphan Medical February 1999
7
Elitek 17 45 RASBURICASE sanofi-aventis October 2009
8
Elliotts B Solution 17 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
9
Folotyn 17 45 PRALATREXATE Allos Therapeutics September 2009
10
Imbruvica 17 45 IBRUTINIB Pharmacyclics November of 2013/February 2014
11
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
12
Istodax 17 45 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
13
Kyprolis 17 45 CARFILZOMIB Onyx Pharmaceuticals July 2012
14
Mozobil 17 45 PLERIXAFOR Genzyme December 2008
15
Neumega 17 OPRELVEKIN Genetics Institute November 1997
16
Revlimid 17 45 LENALIDOMIDE Celgene June 2013
17
Rituxan 17 45 RITUXIMAB Biogen IDEC, Genentech November 1997
18
Targretin 17 45 bexarotene VALEANT LUXEMBOURG 12/29/1999
19
Treanda 17 45 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
20
UVADEX 17 METHOXSALEN Therakos February 1999
21
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
22
Velcade 17 45 BORTEZOMIB Millennium Pharmaceuticals May 2003
23
Xalkori 17 45 CRIZOTINIB Pfizer August of 2011
24
Zevalin 17 45 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
25
Zydelig 17 45 IDELALISIB Gilead July 2014
26
Zykadia 17 45 CERITINIB Novartis April 2014
27
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 950)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
9
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1 29767-20-2 34698
10
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 170729-80-3 6918365 151165
11
Fosaprepitant Approved Phase 4,Phase 2,Phase 1,Early Phase 1 172673-20-0 219090
12
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
13
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 81103-11-9 84029
14
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
15
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 302962-49-8 3062316
16
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
17
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
18
Asparaginase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9015-68-3
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
20
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 130167-69-0
21
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
22
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
23
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
26
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
27
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53643-48-4, 59917-39-4 40839
28
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
29
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
30
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
31
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
32
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 153559-49-0 82146
33
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
34
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 21704 32326
35
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
36
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
37
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 298-81-7 4114
38
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 460612 4053
39
Granisetron Approved, Investigational Phase 4,Phase 2 109889-09-0 3510
40
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 135729-56-5, 119904-90-4 148211
41
Amifostine Approved, Investigational Phase 4,Phase 2,Phase 1 20537-88-6 2141
42 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
43
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
44
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
45
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
46
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
47
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
48
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-75-2 4033
49
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3375-50-6 598
50
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373

Interventional clinical trials:

(show top 50) (show all 6250)

# Name Status NCT ID Phase Drugs
1 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
2 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4 Rituximab
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
4 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Unknown status NCT02290132 Phase 4 Rabbit Anti-human Thymocyte Globulin (ATG)
5 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
6 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
7 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
8 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
9 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
10 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
11 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
12 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
13 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
14 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
15 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
16 An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease. Completed NCT00440817 Phase 4
17 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
18 Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands Completed NCT00731536 Phase 4
19 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
20 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Completed NCT01833039 Phase 4 Ibrutinib
21 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
22 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
23 Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients Completed NCT02108444 Phase 4
24 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
25 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
26 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
27 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
28 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
29 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
30 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
31 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
32 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
33 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
34 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
35 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
36 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
37 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
38 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
39 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
40 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
41 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
42 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
43 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
44 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
45 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
46 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
47 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
48 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
49 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
50 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 28

Anatomical Context for Lymphoma

MalaCards organs/tissues related to Lymphoma:

38
B Cells, T Cells, Bone, Bone Marrow, Lung, Myeloid, Thyroid

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 23468)
# Title Authors Year
1
Post-transplant lymphoproliferative disease with features of cutaneous natural killer/T-cell lymphoma. ( 29380362 )
2018
2
Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017;123:4411-4418. ( 29406586 )
2018
3
Intravascular lymphoma presenting with postural hypotension. ( 29378736 )
2018
4
Response to "Why the Micromort Concept Falls Short in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk Analysis". ( 29365059 )
2018
5
Complete response of diffuse large B-cell lymphoma after direct-acting antiviral therapy for hepatitis C virus. ( 29432921 )
2018
6
Accelerated, untargeted metabolomics analysis of cutaneous T-cell lymphoma reveals metabolic shifts in plasma and tumor adjacent skins of xenograft mice. ( 29160924 )
2018
7
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
8
Hodgkin's Lymphoma Presenting With Extensive Chest Wall Muscle Involvement in an Adult. ( 29452117 )
2018
9
Primary CNS Lymphoma vs. Tumefactive Multiple Sclerosis: A Diagnostic Challenge. ( 29290197 )
2018
10
Indolent, waxing and waning cutaneous presentation of HTLV-1-associated adult T-cell leukemia/lymphoma in an HIV-1-positive patient. ( 29094771 )
2018
11
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. ( 29148847 )
2018
12
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )
2018
13
Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma. ( 29403168 )
2018
14
Can we improve on ibrutinib in mantle cell lymphoma? ( 29396093 )
2018
15
Lenograstim 5 A/g/kg is not superior to biosimilar filgrastim 10 A/g/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. ( 29446445 )
2018
16
Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. ( 29323247 )
2018
17
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
18
A case of primary central nervous system lymphoma arising at the site of remote herpes encephalitis. ( 29382621 )
2018
19
Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort. ( 29273217 )
2018
20
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. ( 29090524 )
2018
21
Some diffuse large B-cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity. ( 29393528 )
2018
22
Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. ( 29428971 )
2018
23
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )
2018
24
Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report. ( 29419676 )
2018
25
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
26
Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. ( 29423097 )
2018
27
Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma. ( 29416774 )
2018
28
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )
2018
29
Caspofungin resistant disseminated candidiasis in a 7-year-old girl with T cell lymphoma: a case report. ( 29441283 )
2018
30
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. ( 29435074 )
2018
31
A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies. ( 29411267 )
2018
32
Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients. ( 29415639 )
2018
33
Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. ( 29449683 )
2018
34
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). ( 29397528 )
2018
35
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
36
Systemic diffuse large B-cell lymphoma masquerading as neovascular glaucoma. ( 29380792 )
2018
37
Two for One: B-Cell Lymphomas with Features of Marginal and Follicular Lymphomas. ( 29408811 )
2018
38
Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant? ( 29415598 )
2018
39
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
40
Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib. ( 29310482 )
2018
41
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. ( 29396091 )
2018
42
Random skin biopsy for diagnosis of intravascular large B-cell lymphoma in a patient with hypoxemia and normal lung imaging. ( 29387769 )
2018
43
Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )
2018
44
Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. ( 29424927 )
2018
45
Adult T cell leukemia/lymphoma with different pathological features in each tumor site. ( 29427186 )
2018
46
Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients. ( 29363157 )
2018
47
Identification of novel recurrent ETV6-IGH fusions in primary central nervous system lymphoma. ( 29432597 )
2018
48
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. ( 29112015 )
2018
49
Primary cutaneous anaplastic large-cell lymphoma: A case report. ( 29369180 )
2018
50
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018